TaperCommunity
Most people start tapering by cutting their dose in equal chunks, say 10% every few weeks, and wonder why the final steps feel so much harder than the first ones. The answer lies in pharmacology, not willpower. Hyperbolic tapering explains this disconnect and offers a framework that maps dose reductions to what actually happens at the receptor level. Understanding it changes how you plan, how you pace yourself, and how you interpret what your body is telling you. This article walks through the science plainly, explains the practical math, and shows why hyperbolic tapering is now the approach supported by the strongest evidence in the deprescribing literature.
When someone says "I'm tapering 10% every month," they usually mean 10% of the original dose. So if they started on 20mg, they cut 2mg each month: 20mg, 18mg, 16mg, and so on. This is linear tapering, and it feels logical on paper.
The trouble is that your brain does not respond to dose in a linear way. The relationship between how much drug you take and how many receptors that drug occupies follows a hyperbolic curve. This is called the hyperbolic dose-response relationship, and it has been well-established in pharmacology for decades. It means that the first milligrams of a drug produce a large change in receptor occupancy, while later milligrams produce progressively smaller additional effects.
For a drug like fluoxetine (Prozac), 20mg occupies roughly 80% of serotonin transporters. Dropping to 10mg drops occupancy to about 60%. That reduction of 20 percentage points corresponds to a 10mg reduction. But dropping from 2mg to 0mg also produces a roughly 20-percentage-point shift in receptor occupancy, yet you are only removing 2mg of drug. The absolute dose change gets smaller, but the neurological impact stays proportionally the same.
This is why people who have cut their dose to 1mg or 2mg still experience significant withdrawal symptoms. They are not being dramatic or unusually sensitive. Their nervous system is experiencing a change at the receptor level that is proportionally comparable to far larger cuts made at higher doses.
Hyperbolic tapering recalibrates your reduction schedule so that each cut produces a roughly equal change in receptor occupancy rather than an equal change in milligrams. Because of the hyperbolic dose-response curve, this means reducing by smaller and smaller amounts in absolute terms as you descend toward zero.
If you are tapering an antidepressant and using a hyperbolic schedule, your reductions might look like this: from 20mg to 10mg (a 10mg cut), then from 10mg to 7mg (a 3mg cut), then from 7mg to 5mg (a 2mg cut), then from 5mg to 3mg, and so on down to fractions of a milligram before the final jump to zero. Each step feels roughly equivalent to your nervous system even though the milligrams look dramatically different.
The term "hyperbolic" refers to the mathematical shape of the curve governing receptor occupancy, not to anything exaggerated or extreme about the method itself. It is precise in a way that linear or percentage-based tapering often is not.
The scientific foundation for hyperbolic tapering in psychiatric medication deprescribing was significantly advanced by Mark Horowitz and David Taylor in their 2019 paper published in Lancet Psychiatry, "Tapering of SSRI treatment to mitigate withdrawal symptoms." Horowitz and Taylor used pharmacological modeling to show that receptor occupancy changes are hyperbolic, not linear, and argued that tapering schedules should reflect this.
They applied this framework to SSRI occupancy of the serotonin transporter (SERT), demonstrating that a dose reduction from 20mg to 10mg of fluoxetine produced a change in SERT occupancy comparable to reducing from 2mg to 1mg. Their analysis challenged the common "10% per month" rule that had been widely recommended without a pharmacological basis, and made the case that reductions should be calibrated to receptor occupancy rather than raw milligrams.
This work contributed directly to updated clinical guidelines. The 2023 Maudsley Deprescribing Guidelines, authored by Horowitz and Taylor alongside colleagues, formally recommend hyperbolic tapering as the preferred approach for antidepressant discontinuation. The guidelines provide specific protocols for commonly prescribed medications and include guidance on how to prepare dose reductions using liquid formulations, pill cutters, and compounding pharmacies, since most pill formats are not designed with slow tapering in mind.
The underlying pharmacological principle also applies to benzodiazepines and other GABAergic drugs, though the receptor dynamics differ in important ways. Professor Heather Ashton's work at Newcastle University, compiled in what is commonly known as the Ashton Manual, described individualized, gradual tapers for benzodiazepines decades before hyperbolic tapering became widely discussed for antidepressants. Ashton emphasized that the pace of reduction matters far more than the method itself, a view that aligns well with the hyperbolic framework.
One of the most common experiences in tapering is that the final stretch is unexpectedly brutal compared to the early reductions. Someone might cut from 20mg to 10mg without much difficulty, then struggle profoundly trying to go from 2mg to 0mg. Hyperbolic tapering explains this pattern precisely.
Going from 20mg to 10mg of an SSRI drops SERT occupancy from roughly 80% to 60%, a 20-point shift. Going from 2mg to 0mg drops SERT occupancy from roughly 20% to 0%, another 20-point shift. The nervous system experiences these as similar-sized changes even though one is a 50% dose reduction and the other is a 100% dose reduction. If you have been cutting by fixed percentages, your pace accelerated without you realizing it, and the final steps effectively ask your brain to adapt to larger neurological changes more rapidly than the early steps did.
Understanding this reverses the usual narrative of failure. The difficulty at low doses is not evidence of psychological dependence or a character flaw. It is evidence that the schedule was not calibrated to the pharmacology. Switching to a hyperbolic approach, even partway through a taper, can reintroduce stability and allow a smoother descent.
The precise calculation requires knowing the dose-occupancy curve for your specific medication, which has been modeled for common SSRIs but is less established for others. The general approach is to reduce by a fixed percentage of your current dose at each step, not a fixed percentage of your starting dose. This is sometimes called "10% of current dose" and approximates hyperbolic tapering reasonably well, though the intervals between reductions matter too.
For someone starting at 20mg using a 10%-of-current-dose approach: 20mg, 18mg, 16.2mg, 14.6mg, 13.1mg, and so on. As doses get lower, the cuts become very small in absolute terms. Eventually you may be reducing by fractions of a milligram per step, which is why specialized tools become necessary.
Liquid formulations of many medications can be obtained through compounding pharmacies or, in some cases, purchased as FDA-approved oral solutions. Splitting tablets works for early reductions but quickly becomes imprecise as the amounts get smaller. Water titration, which involves dissolving a tablet in a known volume of water and drawing off small amounts, is a practical and cost-effective option for many drugs. The Maudsley Deprescribing Guidelines provide specific protocols for each major medication class.
It is worth noting that the pace between reductions matters as much as the size of each cut. Hyperbolic tapering addresses the size of reductions; you still need enough time between each step for your nervous system to stabilize. Most clinicians familiar with this approach recommend holding each new dose for a minimum of two to four weeks, and longer if symptoms are present.
Hyperbolic tapering does not guarantee a symptom-free experience, but it does reduce the likelihood of severe or prolonged withdrawal. If significant symptoms emerge after a reduction, this is feedback, not failure. It suggests the cut was either too large, the interval too short, or both.
Common discontinuation symptoms include dizziness, flu-like feelings, irritability, insomnia, electric-shock sensations (often called "brain zaps"), and emotional volatility. These symptoms overlap with anxiety and depression, which can make it difficult to distinguish withdrawal from a re-emergence of the original condition. Hyperbolic tapering research acknowledges this ambiguity directly. Horowitz and Taylor note that withdrawal symptoms typically begin within a few days of a dose change and tend to resolve within a few weeks, while relapse typically emerges more slowly and often involves the full pattern of the original illness rather than new physical symptoms.
If symptoms are significant, the appropriate response is usually to hold at the current dose until they resolve, or to updose slightly and stabilize before continuing. Attempting to push through severe symptoms by holding for just a day or two before the next cut tends to accumulate stress rather than resolve it. The nervous system adapts on its own timeline, and trying to outpace that adaptation causes more harm than taking a longer hold.
The most common practical barrier to hyperbolic tapering is that standard medication formats are not built for it. A 10mg tablet cannot be conveniently split into 0.5mg pieces. This creates a real access problem, particularly for people who cannot afford compounding or who have doctors unfamiliar with these methods.
Some medications have approved liquid forms that simplify the process considerably. Fluoxetine (Prozac), for instance, is available as a 20mg/5ml oral solution in many countries, which makes very small reductions straightforward without compounding. For others, clinician-supervised liquid compounding is the most reliable path.
Water titration is a widely used workaround that requires only basic kitchen materials. You dissolve a tablet in a specific volume of water, shake thoroughly, and drink a measured portion while discarding the rest. This allows reductions to the nearest milliliter and has been used successfully by many taperers for drugs that dissolve reasonably well. It does not work for all formulations, particularly extended-release tablets, and is not precise enough for every scenario, but it fills an important gap when compounding is not available.
Having a prescriber who understands hyperbolic tapering is valuable, though not always easy to find. The Maudsley Deprescribing Guidelines are freely accessible and can be shared with a doctor who is willing to learn. Some people have found success approaching the conversation by focusing on the published research rather than asking the doctor to take a specific position.
The pharmacological principle applies broadly, but the specific research on receptor occupancy has been most developed for SSRIs and SNRIs. Benzodiazepines follow different receptor dynamics (GABA-A receptor allosteric modulation), but the same general logic holds: the last milligrams have outsized neurological effects, and reductions should become smaller in absolute terms as you descend. The Ashton Manual provides a framework for benzodiazepine tapers that aligns with this thinking.
The "10% method" can refer to two different things. If it means 10% of the original dose cut each month, it is linear and does not account for the hyperbolic curve. If it means 10% of the current dose at each step, it approximates hyperbolic tapering reasonably well. The distinction matters most at lower doses. Using 10% of current dose, your reductions become smaller over time, which is closer to what the pharmacology actually requires.
This varies enormously depending on the medication, the starting dose, how long you have been on it, and individual sensitivity. Many people find that a hyperbolic taper from a standard antidepressant dose takes one to two years or longer when done carefully. This can feel discouraging, but it compares favorably to the alternative of a rapid taper followed by months of severe discontinuation symptoms.
Yes. If you have already been tapering and are experiencing difficulties, you can stabilize at your current dose and restart with a hyperbolic schedule from that point. There is no requirement to return to your original dose. Stabilizing means holding your current dose until symptoms have resolved, which may take several weeks.
Not necessarily. Liquid formulations, water titration, and careful tablet splitting cover many situations, particularly at higher doses where precision is less critical. At very low doses (below 1-2mg for most medications), a compounding pharmacy or a commercially available liquid formulation usually becomes necessary to achieve the small reductions the schedule requires.
Hyperbolic tapering is not a fringe idea or an unsupported preference. It follows directly from the pharmacological properties of the drugs themselves, and it is now formally supported by major deprescribing guidelines. If your taper has been difficult, especially at lower doses, the schedule itself may be the issue rather than your capacity to tolerate change.
If you are navigating this process, taper.community exists as a peer support space for people doing exactly this. Members share practical experience with water titration, compounding, pacing, and the psychological side of long tapers. You are welcome to join and ask questions.
This article is for informational purposes only and does not constitute medical advice. Medication changes should always be made with the guidance of a qualified healthcare provider who can assess your individual circumstances.